niclosamid
oral
antihelminth
drug
use
treat
parasit
infect
million
peopl
worldwid
howev
recent
studi
indic
niclosamid
may
broad
clinic
applic
treatment
diseas
caus
parasit
diseas
symptom
may
includ
cancer
bacteri
viral
infect
metabol
diseas
type
ii
diabet
nash
nafld
arteri
constrict
endometriosi
neuropath
pain
rheumatoid
arthriti
sclerodermat
graftversushost
diseas
system
sclerosi
among
underli
mechan
associ
drug
action
niclosamid
uncoupl
oxid
phosphoryl
modul
notch
signal
pathway
provid
brief
overview
biolog
activ
niclosamid
potenti
clinic
applic
challeng
use
new
therapi
system
diseas
niclosamid
discov
bayer
chemotherapi
research
laboratori
origin
develop
molluscicid
kill
snail
intermedi
host
schistosomiasi
market
bayluscid
scientist
bayer
found
effect
human
tapeworm
cestoda
infect
market
yomesan
human
use
niclosamid
approv
us
fda
use
human
treat
tapeworm
infect
includ
world
health
organ
list
essenti
medicin
use
safe
treat
million
patient
widelyus
drug
niclosamid
mechan
action
welldelin
although
report
involv
uncoupl
oxid
phosphoryl
past
sever
year
mount
evid
accumul
niclosamid
multifunct
drug
abl
inhibit
regul
multipl
signal
pathway
biolog
process
suggest
may
develop
novel
treatment
helminth
diseas
adrenocort
carcinoma
rare
aggress
endocrin
cancer
surgic
resect
effect
therapi
limit
benefit
satoh
et
al
screen
small
molecul
librari
contain
drug
approv
human
use
luciferasecoupl
atp
quantit
assay
assess
cell
viabil
niclosamid
found
inhibit
adrenocort
carcinoma
cellular
prolifer
associ
apoptosi
reduct
epithelialtomesenchym
transit
level
addit
mitochondri
uncoupl
activ
observ
cancer
cell
oral
administr
niclosamid
led
tumor
growth
inhibit
observ
toxic
breast
cancer
lead
caus
death
women
develop
new
therapi
necessari
reduc
mortal
lu
et
al
report
niclosamid
inhibit
signal
promot
wnt
coreceptor
degrad
breast
cancer
cell
subsequ
group
report
niclosamid
act
synergist
monoclon
antibodi
specif
activ
trail
death
receptor
inhibit
tumor
growth
basallik
breast
cancer
fonseca
et
al
report
niclosamid
inhibit
signal
breast
cancer
cell
mechanist
studi
indic
niclosamid
lower
cytoplasm
ph
may
indirectli
lead
inhibit
signal
niclosamid
also
found
prevent
convers
nonbreast
cancer
stem
cell
cancer
stem
cell
mechan
associ
inhibit
signal
transduct
pathway
ren
et
al
identifi
niclosamid
potent
inhibitor
abl
suppress
transcript
activ
use
cellbas
dual
luciferas
report
assay
wang
et
al
use
highthroughput
drug
screen
breast
cancer
spheroid
growth
found
niclosamid
inhibit
format
breast
cancer
spheroid
induc
apoptosi
vitro
tumor
growth
vivo
karaka
et
al
report
niclosamid
enhanc
antitumor
activ
palladium
ii
saccharin
complex
terpyridin
lead
enhanc
cytotox
activ
breast
cancer
stem
cell
tripleneg
breast
cancer
defin
lack
express
estrogen
progesteron
receptor
lack
amplif
account
breast
cancer
lack
effect
therapi
yin
et
al
report
niclosamid
inhibit
ioniz
radiationinduc
signal
tripleneg
breast
cancer
cell
vitro
vivo
liu
et
al
report
niclosamid
alon
combin
cisplatin
repress
growth
xenograft
cisplatinresist
tripleneg
breast
cancer
cell
found
niclosamid
revers
epithelialtomesenchym
transit
phenotyp
inhibit
akt
erk
src
signal
pathway
inhibit
prolifer
cisplatinsensit
cs
cisplatinresist
cr
tripleneg
breast
cancer
cell
vitro
niclosamid
alon
combin
cisplatin
also
could
repress
growth
xenograft
mice
bear
either
cell
colorect
cancer
second
lead
caus
cancerrel
death
unit
state
current
chemotherapi
regimen
target
one
import
underli
patholog
mechan
wnt
signal
pathway
fda
approv
drug
target
pathway
function
wnt
ligand
bind
cell
surfac
frizzl
receptor
activ
dishevel
protein
stabil
constitut
degrad
apc
complex
allow
accumul
transloc
nucleu
alter
gene
transcript
tcflef
transcript
factor
screen
small
molecul
librari
contain
fdaapprov
drug
high
throughput
screen
use
intern
cell
surfac
identifi
niclosamid
small
molecul
inhibitor
signal
niclosamid
promot
wnt
receptor
endocytosi
downregul
protein
inhibit
cytosol
stabil
inhibit
tcflef
gene
report
activ
niclosamid
inhibit
growth
colon
cancer
cell
human
patient
vitro
vivo
regardless
mutat
apc
known
wnt
respons
gene
sack
et
al
creat
promoterdriven
luciferas
report
assay
human
colorect
cancer
cell
order
screen
chemic
librari
compound
affect
gene
transcript
identifi
niclosamid
inhibitor
gene
transcript
niclosamid
reduc
mrna
protein
express
inhibit
colon
cell
migrat
invas
prolifer
coloni
format
vitro
also
reduc
liver
metastasi
mous
model
suliman
et
al
measur
growth
inhibit
apoptosi
three
colon
cancer
cell
line
lovo
ad
treatment
niclosamid
found
niclosamid
treatment
associ
inhibit
notch
signal
pathway
increas
express
tumor
suppressor
famili
glioblastoma
common
primari
brain
tumor
respons
highest
mortal
among
brain
tumor
current
therapi
effect
reduc
mortal
wieland
et
al
employ
cell
viabil
assay
screen
small
collect
synthet
natur
compound
found
niclosamid
select
inhibit
glioblastoma
cell
viabil
detail
mechan
studi
reveal
niclosamid
suppress
wnt
notch
mtor
signal
pathway
preexposur
niclosamid
significantli
diminish
malign
potenti
glioma
cell
vivo
head
neck
cancer
group
biolog
similar
cancer
aris
lip
oral
caviti
nasal
caviti
pharynx
larynx
paranas
sinus
common
type
head
neck
cancer
squamou
cell
carcinoma
head
neck
cancer
account
cancer
death
unit
state
li
et
al
report
inhibit
egfr
erlotinib
fdaapprov
therapeut
agent
led
activ
signal
head
neck
cancer
cell
effect
may
respons
reduc
therapeut
efficaci
erlotinib
head
neck
cancer
abil
niclosamid
inhibit
signal
led
growth
inhibit
head
neck
cancer
cell
vitro
vivo
enhanc
antitumor
effect
elrotinib
leukemia
cancer
bone
marrow
stem
cell
bone
marrowderiv
progenitor
result
high
number
abnorm
white
blood
cell
circul
bloodform
tissu
includ
bone
marrow
lymphat
system
case
leukemia
diagnos
annual
us
notch
signal
pathway
import
gener
hematopoiet
stem
cell
activ
notch
receptor
cleav
releas
notch
intracellular
domain
nicd
move
nucleu
bind
transcript
factor
alter
gene
express
wang
et
al
employ
luciferas
report
system
search
small
molecul
modul
notch
signal
identifi
niclosamid
inhibitor
endogen
notch
signal
aml
cell
cell
line
deriv
acut
myelogen
leukemia
patient
jin
et
al
determin
niclosamid
inhibit
report
activ
increas
level
reactiv
oxygen
speci
ro
aml
cell
niclosamid
synergist
chemotherapeut
agent
cytarabin
etoposid
daunorubicin
vitro
inhibit
growth
aml
cell
implant
nude
mice
recent
jin
et
al
report
niclosamid
decreas
longterm
engraft
chronic
myelogen
leukemia
cml
stem
cell
implant
immunodefici
nog
mice
prolong
surviv
mice
bear
leukemia
cell
driven
human
bcrabl
gene
fusion
common
chromosom
transloc
mutant
driver
leukemia
mechan
may
involv
disrupt
posit
feedback
loop
result
impair
selfrenew
capac
surviv
cml
lung
cancer
second
common
cancer
highest
mortal
rate
unit
state
patient
nonsmal
cell
lung
cancer
nsclc
harbor
mutat
egfr
gene
promot
cancer
cell
growth
egfr
inhibitor
eg
erlotinib
deploy
drug
resist
emerg
mitig
effect
class
agent
li
et
al
found
erlotinib
resist
associ
activ
signal
niclosamid
treatment
overcam
erlotinib
resist
niclosamid
combin
erlotinib
potent
repress
growth
erlotinibresist
lung
cancer
cell
xenograft
increas
apoptosi
tumor
research
group
subsequ
report
niclosamid
effect
reduc
radioresist
human
lung
cancer
vitro
vivo
mechan
involv
inhibit
activ
induc
radiat
lee
et
al
use
cell
viabil
screen
determin
niclosamid
enhanc
radiosensit
nonsmal
cell
lung
cancer
cell
line
suggest
niclosamid
may
use
radiosensit
lung
cancer
patient
osteosarcoma
common
primari
bone
malign
osteosarcoma
patient
surviv
improv
minim
despit
advanc
surgic
techniqu
chemotherapeut
regimen
liao
et
al
report
niclosamid
effect
inhibit
osteosarcoma
cell
prolifer
migrat
surviv
inhibitori
effect
associ
decreas
express
cfo
cjun
cmyc
niclosamid
also
inhibit
osteosarcoma
tumor
growth
mous
xenograft
tumor
model
ovarian
cancer
account
cancer
women
yo
et
al
screen
bioactiv
compound
librari
inhibit
spheroid
format
cisplatinresist
ovarian
cancer
cell
identifi
niclosamid
activ
drug
assay
subsequ
niclosamid
found
inhibit
ovarian
tumoriniti
cell
vitro
vivo
alter
metabol
pathway
haygood
et
al
isol
ovarian
cancer
tumor
sphere
patient
treat
concurr
niclosamid
analog
carboplatin
observ
cytotox
combin
drugtreat
sampl
wnt
respons
gene
inhibit
king
et
al
show
express
highli
correl
ovarian
carcinoma
direct
transcript
target
signal
niclosamid
abrog
signal
decreas
transcript
activ
cell
viabil
increas
cell
death
oral
niclosamid
inhibit
tumor
growth
progress
human
ovarian
cancer
xenograft
anim
model
prostat
cancer
common
cancer
among
men
unit
state
lead
caus
cancer
death
among
men
mani
prostat
tumor
androgendepend
antiandrogen
import
therapeut
enzalutamid
new
antiandrogen
treatment
metastat
castrationresist
prostat
cancer
resist
enzalutamid
therapi
report
associ
express
androgen
receptor
splice
variant
includ
isoform
liu
et
al
employ
androgenstimul
luciferas
activ
assay
identifi
potenti
drug
activ
isoform
found
niclosamid
downregul
protein
express
inhibit
transcript
activ
reduc
recruit
prostatespecif
antigen
promot
niclosamid
also
inhibit
prostat
cancer
cell
growth
vitro
tumor
growth
vivo
synerg
enzalutamid
inhibit
growth
enzalutamideresist
tumor
indic
potenti
applic
patient
enzalutamid
resist
subsequ
liu
et
al
found
niclosamid
inhibit
activ
prostat
cancer
cell
niclosamid
synergist
revers
enzalutamid
resist
prostat
cancer
cell
combin
treatment
niclosamid
plu
enzalutamid
result
inhibit
coloni
format
growth
arrest
induc
cell
apoptosi
mechan
niclosamid
overcom
enzalutamid
resist
may
associ
downregul
target
gene
prevent
recruit
androgen
receptor
prostatespecif
antigen
promot
prostat
cancer
cell
manner
result
suggest
niclosamid
may
target
pathway
overcom
enzalutamid
resist
inhibit
tumor
cell
migrat
invas
advanc
prostat
cancer
known
therapeut
agent
includ
androgendepriv
therapi
chemotherapeut
agent
radiotherapi
induc
neuroendocrin
differenti
prostat
cancer
cell
differenti
cell
lack
express
androgen
receptor
prostat
specif
antigen
resist
treatment
ippolito
et
al
report
abil
niclosamid
inhibit
mitochondri
function
associ
acid
ph
prostat
neuroendocrin
cancer
cell
niclosamid
phdepend
toxic
castrationresist
neuroendocrin
prostat
cancer
cell
line
renal
cell
carcinoma
origin
epithelium
renal
tubul
common
type
kidney
cancer
adult
resist
current
avail
therapi
zhao
et
al
discov
niclosamid
inhibit
prolifer
anchorageindepend
coloni
format
two
renal
cell
carcinoma
cell
line
niclosamid
synerg
cisplatin
reduc
tumor
growth
two
vivo
renal
cell
carcinoma
xenograft
mous
model
mechan
involv
decreas
express
mitochondri
dysfunct
number
studi
investig
use
niclosamid
potenti
therapeut
agent
variou
cancer
tumor
type
grow
rapidli
summari
niclosamid
mechan
action
cancer
cite
within
provid
tabl
tuberculosi
secondmost
common
caus
death
infecti
diseas
effort
overcom
multidrug
resist
ovarian
cancer
inhibit
alter
metabol
pathway
prostat
cancer
downregul
protein
express
pathway
inhibit
intracellular
acidif
induct
renal
cell
carcinoma
inhibit
signal
current
therapi
sun
et
al
test
abil
antifung
antihelminth
drug
inhibit
growth
tuberculosi
strain
niclosamid
found
inhibit
growth
minimum
inhibitori
concentr
author
suggest
topic
use
treat
surfaceloc
tuberculosi
ie
skin
intestin
tuberculosi
infect
subsequ
number
research
group
report
abil
niclosamid
relat
salicylanilid
deriv
inhibit
growth
tuberculosi
report
effect
ph
growth
inhibit
anthrax
zoonot
diseas
caus
infect
bacillu
anthraci
despit
develop
anthrax
vaccin
diseas
remain
public
health
threat
zhu
et
al
use
establish
imagebas
assay
monitor
endocytosi
transloc
betalactamasefus
anthrax
lethal
factor
identifi
small
molecul
block
anthrax
toxin
intern
found
niclosamid
protect
macrophag
cho
cell
expos
anthrax
lethal
toxin
also
defend
cell
pseudomona
exotoxin
diphtheria
toxin
one
mechan
niclosamid
action
may
involv
endosom
acidif
mani
bacteria
use
quorum
sens
coordin
certain
behavior
biofilm
format
virul
antibiot
resist
imperi
et
al
screen
librari
fdaapprov
drug
abil
inhibit
quorum
sens
respons
gramneg
pathogen
pseudomona
aeruginosa
identifi
niclosamid
inhibitor
p
aeruginosa
quorum
sens
respons
product
acylhomoserin
lacton
quorum
sens
signal
molecul
niclosamid
affect
transcript
gene
p
aeruginosa
high
degre
target
specif
toward
quorum
sensingdepend
gene
also
suppress
surfac
motil
product
secret
virul
factor
elastas
pyocyanin
rhamnolipid
reduc
biofilm
format
niclosamid
also
protect
galleria
mellonella
moth
larva
p
aeruginosa
infect
staphylococcu
aureu
gramposit
bacterium
methicillinresist
aureu
mrsa
mainli
respons
hospit
communityacquir
infect
rajamuthiah
et
al
establish
caenorhabd
elegan
whole
anim
liquid
mrsa
infect
high
throughput
screen
assay
identifi
small
molecul
prolong
surviv
infect
c
elegan
nematod
screen
biomol
librari
fdaapprov
drug
niclosamid
one
posit
hit
prolong
nematod
surviv
niclosamid
inhibit
growth
methicillinresist
aureu
well
anoth
gramposit
bacteria
enterococcu
faecium
effect
gramneg
speci
pseudomona
aeruginosa
niclosamid
shown
bacteriostat
oxyclozanid
relat
salicylanilid
deriv
also
effect
mrsa
bacteria
shown
bactericid
thu
niclosamid
may
util
treat
methicillinresist
aureu
mrsa
infect
pandem
viral
infect
import
public
health
threat
strategi
control
viral
infect
mainli
use
two
approach
agent
target
viru
directli
agent
target
host
niclosamid
report
potenti
agent
host
defens
viral
infect
wu
et
al
screen
small
chemic
librari
consist
market
drug
abil
prevent
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
found
niclosamid
inhibit
sarscov
replic
protect
vero
cell
cytopath
effect
viru
infect
niclosamid
effect
antivir
host
defens
mechan
first
report
jurgeit
et
al
use
monoclon
antibodi
stain
viral
dsrna
infect
cell
readout
imagedbas
screen
screen
librari
known
bioactiv
compound
identifi
niclosamid
potent
low
micromolar
inhibitor
phdepend
human
rhinovirus
hrv
influenza
viru
mechan
action
propos
relat
niclosamid
protonophor
activ
abil
act
proton
carrier
previous
describ
niclosamid
thu
could
candid
hostdirect
antivir
therapi
chikungunya
viru
member
famili
togavirida
enter
cell
receptormedi
endocytosi
wang
et
al
use
chikungunya
viru
insect
cell
fusion
inhibit
assay
highthroughput
assay
screen
fdaapprov
drug
librari
identifi
niclosamid
antichikungunya
viru
activ
reduc
chikungunya
viru
entri
transmiss
zika
viru
zikv
mosquitoborn
flaviviru
grow
public
health
concern
follow
larg
outbreak
start
brazil
xu
et
al
use
zikvinduc
activ
cell
drug
screen
inhibitor
identifi
niclosamid
inhibitor
zikv
replic
brain
organoid
combin
treatment
niclosamid
plu
nonselect
pancaspas
inhibitor
caspas
activ
increas
protect
human
neural
progenitor
astrocyt
zikvinduc
cell
death
metabol
syndrom
seri
metabol
abnorm
associ
surplu
energi
intak
obes
sedentari
lifestyl
grow
public
health
threat
clinic
challeng
worldwid
patient
metabol
syndrom
higher
risk
type
diabet
mellitu
predispos
nonalcohol
fatti
liver
diseas
type
diabet
mellitu
affect
million
american
seventh
lead
caus
death
us
lifestyl
chang
impact
manag
diabet
medic
effect
outcom
patient
often
becom
refectori
therapi
antihelminth
drug
niclosamid
report
uncoupl
oxid
phosphoryl
disrupt
ph
homeostasi
parasit
kill
worm
seek
new
avenu
diabet
treatment
tao
et
al
first
demonstr
water
solubl
form
niclosamid
niclosamid
ethanolamin
salt
uncoupl
mammalian
mitochondria
ad
niclosamid
ethanolamin
salt
food
mice
fed
high
fat
diet
order
achiev
drug
exposur
vivo
overcom
niclosamid
low
exposur
mice
dose
intermitt
found
niclosamid
ethanolamin
salt
treatment
led
reduct
metabol
symptom
increas
rate
energi
expenditur
elev
oxygen
consumpt
rate
increas
lipid
oxid
niclosamid
ethanolamin
salt
prevent
elev
fast
blood
glucos
basal
plasma
insulin
concentr
improv
insulin
sensit
reduc
bodi
weight
gain
mice
fed
high
fat
diet
establish
high
fat
diet
diabet
mous
model
niclosamid
ethanolamin
salt
treatment
revers
metabol
deleteri
effect
similar
result
observ
dbdb
diabet
mice
diabet
develop
due
mutat
leptin
receptor
gene
nonalcohol
fatti
liver
diseas
earli
indic
metabol
syndrom
lipid
abnorm
accumul
liver
world
popul
affect
nonalcohol
fatti
liver
diseas
lead
caus
type
diabet
nonalcohol
steatohepat
nash
cirrhosi
hepatocellular
carcinoma
addit
effect
diabet
symptom
tao
et
al
also
describ
effect
niclosamid
ethanolamin
salt
reduc
liver
fat
accumul
steatosi
mice
fed
high
fat
diet
plu
niclosamid
ethanolamin
salt
author
studi
effect
niclosamid
ethanolamin
salt
human
liver
carcinoma
cell
mous
liver
found
increas
lipid
oxid
stimul
ampactiv
protein
kinas
ampk
phosphoryl
inhibit
acetylcoa
carboxylas
inhibitor
mitochondri
arteri
vasoconstrict
dynam
narrow
blood
arteri
vessel
respons
signal
li
et
al
report
treatment
rat
water
solubl
form
niclosamid
niclosamid
ethanolamin
relax
phenylephrineand
high
k
kpss
induc
vasoconstrict
pretreat
niclosamid
ethanolamin
inhibit
phenylephrineand
kpssinduc
constrict
rat
mesenter
arteri
due
mitochondri
uncoupl
activ
niclosamid
ethanolamin
reduc
cellular
atpadp
ratio
vascular
smooth
muscl
cell
activ
ampactiv
protein
kinas
ampk
activ
smooth
muscl
cell
rat
thorac
aorta
niclosamid
ethanolamin
treatment
increas
cytosol
ca
depolar
mitochondri
membran
vascular
smooth
muscl
cell
result
suggest
niclosamid
potenti
antihypertens
drug
endometriosi
estrogendepend
gynecolog
diseas
result
tissu
normal
grow
insid
uteru
grow
outsid
peritoneum
instead
affect
women
reproduct
age
without
effect
pharmacotherapi
prather
et
al
report
niclosamid
reduc
size
endometriot
implant
mous
model
endometriosi
inhibit
cell
prolifer
inflammatori
signal
pathway
includ
rela
activ
without
disrupt
reproduct
function
femal
mice
neuropath
pain
patholog
condit
affect
popul
worldwid
chronic
pain
eman
damag
diseas
somatosensori
nerv
effect
therapi
ai
et
al
report
niclosamid
lownanomolar
alloster
antagonist
group
metabotrop
glutam
g
proteincoupl
receptor
mglur
high
select
group
homolog
group
iii
mglur
preclin
data
demonstr
mechan
hyperalgesia
model
neuropath
pain
rat
painrel
behavior
revers
niclosamid
treatment
zhang
et
al
report
wnt
signal
underli
pathogenesi
neuropath
pain
niclosamid
inhibitor
wnt
releas
iwr
effect
two
rodent
pain
model
rheumatoid
arthriti
chronic
inflammatori
autoimmun
diseas
may
result
synovi
inflamm
hyperplasia
synovi
tissu
joint
damag
effect
therapi
target
caus
rheumatoid
arthriti
nonspecif
antiinflammatori
treatment
allevi
symptom
liang
et
al
report
niclosamid
reduc
cytokin
express
releas
human
rheumatoid
arthriti
fibroblastlik
synoviocyt
niclosamid
treatment
inhibit
seruminduc
synoviocyt
migrat
invas
produc
alter
filamentousactin
cytoskelet
network
cell
niclosamid
decreas
map
kinas
signal
activ
synoviocyt
addit
niclosamid
treatment
reduc
sever
injuri
collageninduc
arthriti
mous
model
huang
et
al
also
report
niclosamid
induc
apoptosi
human
rheumatoid
arthritisderiv
fibroblastlik
synoviocyt
graftversushost
diseas
may
occur
bone
marrow
stem
cell
transplant
patient
receiv
stem
cell
donor
cell
attack
host
tissu
organ
foreign
diseas
lead
caus
morbid
mortal
transplant
morin
et
al
report
niclosamid
treatment
provid
benefici
immunolog
effect
revers
clinic
symptom
graftversushost
diseas
includ
alopecia
vascul
diarrhea
also
prevent
fibrosi
skin
viscer
organ
sclerodermat
graftversushost
diseas
model
use
balbc
mice
provok
bone
marrow
spleen
cell
transplant
benefici
effect
niclosamid
associ
inhibit
erk
akt
notch
signal
pathway
earlob
skin
mice
system
sclerosi
connect
tissu
disord
character
fibrosi
skin
intern
organ
vascular
alter
dysimmun
includ
presenc
autoantibodi
nuclear
protein
without
defin
patholog
caus
morin
et
al
report
niclosamid
treatment
led
improv
diseas
mous
model
system
sclerosi
induc
hypochlor
acid
niclosamideinduc
inhibit
akt
pathway
observ
identifi
unifi
mechan
underli
niclosamid
pleotrop
biolog
activ
difficult
due
gap
knowledg
target
interact
directli
niclosamid
mani
activ
report
within
unclear
specif
interact
biolog
target
molecul
drive
observ
result
indirect
mechan
oper
combin
occur
studi
address
mechanist
issu
thu
direct
bind
interact
niclosamid
distinct
biolog
target
molecul
establish
account
report
impact
signal
pathway
biolog
observ
cite
within
tabl
niclosamid
abil
act
protonophor
uncoupl
oxid
phosphoryl
affect
ph
balanc
cell
propos
underli
indirect
mechan
account
niclosamid
activ
helminth
activ
activ
mous
model
type
diabet
fatti
liver
diseas
activ
bacteria
virus
activ
antihypertens
model
given
niclosamid
abil
inhibit
signal
transduct
pathway
drive
transcript
multipl
gene
product
like
niclosamid
report
biolog
activ
may
result
crosstalk
signal
pathway
chemic
structur
niclosamid
contain
structur
featur
associ
pleotrop
pharmacolog
activ
niclosamid
member
salicylanilid
class
pharmacolog
agent
deriv
salicyl
acid
imbed
within
class
within
niclosamid
aryl
pharmacophor
motif
structur
motif
resid
larg
number
divers
biolog
natur
product
isol
plant
fungu
bacteria
resid
multipl
approv
medicin
across
varieti
therapeut
categori
repres
exampl
pharmacolog
agent
contain
motif
salicyl
acid
diflunis
aminosalicyl
acid
antimycin
balanol
mycophenol
flavonoid
doxycyclin
daunorubicin
eticloprid
mani
exampl
direct
bind
target
mechan
identifi
given
presenc
structur
motif
surpris
niclosamid
pleotrop
biolog
activ
potenti
interact
multipl
biolog
target
research
need
defin
structureact
relationship
niclosamid
biolog
target
bind
order
identifi
select
agent
defin
underli
mechan
toward
end
recent
structureact
studi
demonstr
niclosamid
effect
atp
homeostasi
separ
effect
wnt
signal
niclosamid
monohydr
dehydr
melt
heat
fusion
kjmol
logd
ph
essenti
insolubl
water
niclosamid
low
oral
toxic
mammal
oral
median
lethal
dose
ld
rat
mgkg
chang
et
al
report
pharmacokinet
paramet
niclosamid
rat
administ
oral
mgkg
niclosamid
exhibit
short
halflif
h
niclosamid
rapidli
absorb
tmax
less
min
cmax
ng
ml
auc
bioavail
respect
osada
et
al
report
pharmacokinet
paramet
mice
oral
dose
mgkg
observ
similar
kinet
profil
also
demonstr
niclosamid
concentr
tumor
tissu
ngg
tissu
similar
plasma
ngml
measur
h
final
administr
concentr
wellbelow
ic
niclosamid
vitro
wnt
signal
cell
growth
assay
treatment
system
diseas
effort
improv
system
exposur
drug
focus
employ
nanotechnolog
prodrug
approach
ye
et
al
use
wet
media
mill
techniqu
prepar
niclosamid
nanocryst
approxim
nm
size
howev
nanocryst
formul
show
signific
improv
plasma
concentr
vs
time
profil
nanocryst
control
niclosamid
administ
intraven
iv
rat
though
increas
tissu
concentr
observ
h
lin
et
al
report
use
singlecapillari
electrospray
method
develop
watersolubl
form
nanoniclosamid
plasma
concentr
niclosamid
nanoformul
via
oral
iv
administr
peak
right
distribut
phase
h
previous
report
recent
group
report
acyl
deriv
niclosamid
significantli
increas
plasma
concentr
durat
exposur
niclosamid
dose
oral
first
report
success
increas
system
drug
exposur
niclosamid
plasma
extend
durat
exposur
order
make
effect
use
niclosamid
addit
work
need
done
improv
solubl
absorpt
system
bioavail
beyond
approv
medic
use
parasit
diseas
treatment
niclosamid
demonstr
preclin
activ
mani
diseas
model
rang
cancer
metabol
diseas
multipl
type
infect
tabl
current
four
clinic
trial
niclosamid
colon
cancer
prostat
cancer
clinicaltri
gov
clinic
trial
registri
other
sure
follow
benefici
effect
niclosamid
appreci
specif
diseas
improv
pharmacolog
pharmacokinet
properti
niclosamid
reformul
prodrug
strategi
approach
make
widespread
use
drug
develop
novel
niclosamid
deriv
bias
toward
target
specif
signal
pathway
biolog
function
specif
system
diseas
second
approach
make
use
remark
power
niclosamid
